If there are clear indications that it may be expected that the active substance does not have any harmful effects on human or animal health or on groundwater or any unacceptable influence on the environment, as set out in Annex V, Article 12(1)(a) and (2)(a) shall apply.
Art. 11b Commission Regulation (EC) No 1490/2002 of 14 August 2002 laying down further detailed r…
Active substance with clear indications that they do not have any harmful effects
Judgment of the General Court (Fourth Chamber) of 19 September 2019. Arysta LifeScience Netherlands BV v European Commission.Decision
By Directive 2008/69/EC of 1 July 2008 amending Directive 91/414 to include clofentezine, dicamba, difenoconazole, diflubenzuron, imazaquin, lenacil, oxadiazon, picloram and pyriproxyfen as active substances (OJ 2008 L 172, p. 9), the …
19 Sep 2019 · 62017TJ0476
Judgment of the Court (Eighth Chamber) of 27 June 2013. Xeda International SA and Pace International LLC v European Commission.Decision
In order to set aside the appellants’ claims that they were deprived of the opportunity, provided for in Article 3(2) of Regulation No 1095/2007, to withdraw their support for the inclusion of DPA in Annex I, due to the delay in carrying …
27 Jun 2013 · 62012CJ0149
Judgment of the General Court (Fourth Chamber) of 14 December 2018. Arysta LifeScience Netherlands BV, formerly Chemtura Netherlands BV v EuDecision
Diflubenzuron was included in Annex I to Directive 91/414 by Commission Directive 2008/69, in accordance with the procedure laid down in Article 11b of Regulation No 1490/2002.
14 Dec 2018 · 62015TJ0725
Commission Implementing Regulation (EU) No 1100/2011 of 31 October 2011 amending Impleme…Law
… 1.] směrnicí Komise 2008/69/ES [Úř. věst. L 172, 2.7.2008, s. 9.] v souladu s postupem stanoveným v článku 11b nařízení Komise (ES) č. 1490/2002 ze dne 14. srpna 2002, kterým se stanoví další prováděcí pravidla pro …